Cited by 995Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPain Management and Opioid Use

The DOI matches its Crossref record; 36 of the 39 references it cites were found in a registry or an index.

Comparative effectiveness of different treatment pathways for opioid use disorder.

Open access

Wakeman, Sarah E., Larochelle, Marc R., Ameli, Omid, Chaisson, Christine E., McPheeters, Jeffrey Thomas, Crown, William H., Azocar, Francisca, Sanghavi, Darshak M.·2020·JAMA Network Open

DOI 10.1001/jamanetworkopen.2019.20622PMC PMC11143463

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective: To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participants: This retrospective comparative effectiveness research study assessed deidentified claims from the OptumLabs Data Warehouse from individuals aged 16 years or older with OUD and commercial or Medicare Advantage coverage. Opioid use disorder was identified based on 1 or more inpatient or 2 or more outpatient claims for OUD diagnosis codes within 3 months of each other; 1 or more claims for OUD plus diagnosis codes for opioid-related overdose, injection-related infection, or inpatient detoxification or residential services; or MOUD claims between January 1, 2015, and September 30, 2017. Data analysis was performed from April 1, 2018, to June 30, 2019. Exposures: One of 6 mutually exclusive treatment pathways, including (1) no treatment, (2) inpatient detoxification or residential services, (3) intensive behavioral health, (4) buprenorphine or methadone, (5) naltrexone, and (6) nonintensive behavioral health. Main Outcomes and Measures: Opioid-related overdose or serious acute care use during 3 and 12 months after initial treatment. Results: A total of 40 885 individuals with OUD (mean [SD] age, 47.73 [17.25] years; 22 172 [54.2%] male; 30 332 [74.2%] white) were identified. For OUD treatment, 24 258 (59.3%) received nonintensive behavioral health, 6455 (15.8%) received inpatient detoxification or residential services, 5123 (12.5%) received MOUD treatment with buprenorphine or methadone, 1970 (4.8%) received intensive behavioral health, and 963 (2.4%) received MOUD treatment with naltrexone. During 3-month follow-up, 707 participants (1.7%) experienced an overdose, and 773 (1.9%) had serious opioid-related acute care use. Only treatment with buprenorphine or methadone was associated with a reduced risk of overdose during 3-month (adjusted hazard ratio [AHR], 0.24; 95% CI, 0.14-0.41) and 12-month (AHR, 0.41; 95% CI, 0.31-0.55) follow-up. Treatment with buprenorphine or methadone was also associated with reduction in serious opioid-related acute care use during 3-month (AHR, 0.68; 95% CI, 0.47-0.99) and 12-month (AHR, 0.74; 95% CI, 0.58-0.95) follow-up. Conclusions and Relevance: Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments. Strategies to address the underuse of MOUD are needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2019.20622

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N. O., & Baldwin, G. T. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,754
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
Self-citation
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014
Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B. A., Iqbal, K., Ward, J. W., & Holtzman, D. J. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.304132 · Cited by 699
The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis
Ciccarone, D. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.01.010 · Cited by 677
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Medications for Opioid Use Disorder Save Lives
Mancher, M., & Leshner, A. (2019) · National Academies Press eBooks · doi:10.17226/25310 · Cited by 473

Flagged first, then by citations

Show all 39 references

3 of the 39 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 995

Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder
Smart, R., Grant, S., Gordon, A. J., Pacula, R. L., & Stein, B. D. (2022) · JAMA Health Forum · doi:10.1001/jamahealthforum.2022.3285 · Cited by 18
Barriers to drug treatment in police diversion programs and drug courts: A qualitative analysis.
Dickson‐Gómez, J., Spector, A. L., Krechel, S., Li, J., Montaque, H. D. G., Ohlrich, J., Galletly, C. L., & Weeks, M. R. (2022) · American Journal of Orthopsychiatry · doi:10.1037/ort0000643 · Cited by 16
Interest without uptake: A mixed-methods analysis of methadone utilization in Kyrgyz prisons
Liberman, A. R., Bromberg, D. J., Litz, T., Kurmanalieva, A., de Leon, S. J. G., Rozanova, J., Azbel, L., Meyer, J. P., & Altice, F. L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276723 · Cited by 16
Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders
Onisiforou, A., Michael, A., Apostolakis, M., Mammadov, E., Mitka, A., Kalatta, M. A., Koumas, M., Georgiou, A. N., Chatzittofis, A., Panayiotou, G., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.09.008 · Cited by 16
Smartphone App–Based Contingency Management and Opioid Use Disorder Treatment Outcomes
Marino, E. N., Karns-Wright, T., Perez, M. C., & Potter, J. S. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.48405 · Cited by 16
Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder
Holtyn, A. F., Toegel, F., Novak, M. D., Leoutsakos, J., Fingerhood, M., & Silverman, K. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108786 · Cited by 15
Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals
Patel, E., Solomon, K. T., Saleem, H. T., Saloner, B. K., Pugh, T., Hulsey, E. G., & Leontsini, E. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108658 · Cited by 17
Rapid Buprenorphine Microdosing for Opioid use Disorder in a Hospitalized Patient Receiving Very High Doses of Full Agonist Opioids for Acute Pain Management: Titration, Implementation Barriers, and Strategies to Overcomes
DeWeese, J. P., Krenz, J. R., Wakeman, S. E., & Peckham, A. M. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1915914 · Cited by 16
Self-citation
Chronic Pain, Opioid Use Disorder, and Clinical Management Among Older Adults
Potru, S., & Tang, Y. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20210002 · Cited by 18
Peer Providers and Linkage with Buprenorphine Care after Hospitalization: A Retrospective Cohort Study
Jack, H. E., Denisiuk, E., Collins, B. A., Stephens, D., Blalock, K. L., Klein, J. W., Bhatraju, E. P., Merrill, J. O., Hallgren, K. A., & Tsui, J. I. (2022) · Substance Abuse · doi:10.1080/08897077.2022.2095078 · Cited by 15
Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies
Landis, R. K., Opper, I., Saloner, B. K., Gordon, A. J., LESLIE, D. L., Sorbero, M., & Stein, B. D. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109669 · Cited by 15
Things We Do for No Reason™: Avoiding methadone for opioid withdrawal
Martín, M., Englander, H. L., & Calcaterra, S. L. (2023) · Journal of Hospital Medicine · doi:10.1002/jhm.13138 · Cited by 15
Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder
Zalmai, R., Hill, L. G., Loera, L. J., Mosgrove, Q., & Brown, C. M. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.06.010 · Cited by 15
Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis
Muthulingam, D., Hassett, T. C., Madden, L. M., Bromberg, D. J., Fraenkel, L., & Altice, F. L. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209138 · Cited by 15
Medication for Opioid Use Disorder After Serious Injection-Related Infections in Massachusetts
Kimmel, S. D., Walley, A. Y., White, L. F., Yan, S., Grella, C. E., Majeski, A., Stein, M. D., Bettano, A. L., Bernson, D., Drainoni, M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21740 · Cited by 15
Self-citation
Emergency Clinician Buprenorphine Initiation, Subsequent Prescriptions, and Continuous Prescriptions
Dekker, A. M., Schriger, D. L., Herring, A. A., & Samuels, E. A. (2025) · JAMA · doi:10.1001/jama.2024.27976 · Cited by 15
Inconsistent Addiction Treatment for Patients Undergoing Cardiac Surgery for Injection Drug Use-associated Infective Endocarditis
Tiako, M. J. N., Hong, S., Mahmood, S. U. B., Mori, M., Mangi, A. A., Yun, J. J., Juthani‐Mehta, M., & Geirsson, A. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000710 · Cited by 15
Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder
Velez, F. F., Luderer, H. F., Gerwien, R. W., Parcher, B., Mezzio, D. J., & Malone, D. C. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1884471 · Cited by 15
Improving transitions of care for patients initiated on buprenorphine for opioid use disorder from the emergency departments in King County, Washington
Fockele, C. E., Duber, H. C., Finegood, B., Morse, S. C., & Whiteside, L. (2021) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12408 · Cited by 15
Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder
Velez, F. F., & Malone, D. C. (2021) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2021.1966187 · Cited by 16
Addiction Nursing Competencies: A Comprehensive Toolkit for the Addictions Nurse.
Wason, K., Potter, A., Alves, J., Loukas, V., Lastimoso, C., Sodder, S., Caputo, A., & Labelle, C. T. (2021) · Journal of Nursing Administration · doi:10.1097/nna.0000000000001041 · Cited by 10
The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs
Lake, S., Kerr, T. H., Buxton, J. A., Walsh, Z., Cooper, Z. D., Socias, M. E., Fairbairn, N. S., Hayashi, K., & Milloy, M. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0080 · Cited by 15
Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs
Adams, J. W., Savinkina, A. A., Fox, A. D., Behrends, C. N., Madushani, R. W. M. A., Wang, J., Chatterjee, A., Walley, A. Y., Barocas, J. A., & Linas, B. P. (2022) · Addiction · doi:10.1111/add.15883 · Cited by 17
Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats
Townsend, E. A., Blough, B. E., Epstein, D. H., Negus, S. S., Shaham, Y., & Banks, M. L. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01393-3 · Cited by 15
Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy
Jarrett, J. B., Bratberg, J. P., Burns, A. L., Cochran, G., DiPaula, B. A., Dopp, A. L., Elmes, A. T., Green, T. C., Hill, L. G., Homsted, F. A. E., et al. (2023) · Substance Abuse · doi:10.1177/08897077231203849 · Cited by 15
Prevalence and risk factors for opioid related mortality among probation clients in an American city
Boulger, J. K., Hinami, K., Lyons, T. P., & Konchak, J. N. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108712 · Cited by 14
Treatment outcomes associated with medications for opioid use disorder (MOUD) among criminal justice-referred admissions to residential treatment in the U.S., 2015–2018
Stahler, G. J., Mennis, J. L., Stein, L. A. R., Belenko, S. R., Rohsenow, D. J., Grunwald, H. E., Brinkley‐Rubinstein, L., & Martin, R. A. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109498 · Cited by 16
Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost
Ahmed, F. Z., Andraka‐Christou, B., Clark, M. H., Totaram, R., Atkins, D. N., & del Pozo, B. (2022) · Health & Justice · doi:10.1186/s40352-022-00188-4 · Cited by 14
An evaluation of the association between specific post‐overdose care services in emergency departments and subsequent treatment engagement
Chambers, L. C., Hallowell, B. D., Samuels, E. A., Daly, M. M., Baird, J. B., & Beaudoin, F. L. (2023) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12877 · Cited by 14
Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities
Wyse, J. J. B., Shull, S., Lindner, S., Morasco, B. J., Gordon, A. J., Carlson, K. F., Korthuis, P. T., Ono, S. S., Liberto, J. G., & Lovejoy, T. I. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08027-4 · Cited by 14
Transcranial direct current stimulation combined with cognitive training improves decision making and executive functions in opioid use disorder: a triple-blind sham-controlled pilot study
Aksu, S., Soyata, A. Z., Şeker, S., Akkaya, G., YILMAZ, Y., Kafalı, T., Evren, C., & Umut, G. (2023) · Journal of Addictive Diseases · doi:10.1080/10550887.2023.2168991 · Cited by 14
μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges
Salinsky, L. M., Merritt, C. R., Zamora, J. C., Giacomini, J. L., Anastasio, N. C., & Cunningham, K. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1239159 · Cited by 14
Police Knowledge, Attitudes, and Beliefs About Opioid Addiction Treatment and Harm Reduction: A Survey of Illinois Officers
Reichert, J., Martins, K. F., Taylor, B. G., & del Pozo, B. (2023) · Journal of Drug Issues · doi:10.1177/00220426231212567 · Cited by 14
Naltrexone Compared With Buprenorphine or Methadone in Pregnancy
Atluru, S., Bruehlman, A., Vaughn, P., Schauberger, C. W., & Smid, M. C. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005510 · Cited by 14
Racial and ethnic inequities in substance use treatment among women with opioid use disorder
Scheidell, J. D., Pitre, M., & Andraka‐Christou, B. (2024) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2023.2291748 · Cited by 14
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
Availability of Medications for Opioid Use Disorder in Community Mental Health Facilities
Cantor, J., Griffin, B. A., Levitan, B., Mendon, S. J., Stein, B. D., Hunter, S. B., & Ober, A. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.17545 · Cited by 14
Treating Opioid Use Disorder and Opioid Withdrawal in the Context of Fentanyl
Martinez, S., Ellis, J. D., Bergeria, C. L., Huhn, A. S., & Dunn, K. E. (2025) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-081423-023518 · Cited by 16
Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among Youth
Krausz, M. R., Westenberg, J. N., Tsang, V. W. L., Suen, J., Ignaszewski, M. J., Mathew, N., Azar, P., Cabanis, M., Elsner, J., Vogel, M., et al. (2022) · Medicina · doi:10.3390/medicina58040539 · Cited by 15
County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019
Corry, B., Underwood, N. L., Cremer, L. J., Rooks-Peck, C. R., & Jones, C. M. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109495 · Cited by 14
Demographic and socioeconomic correlates to buprenorphine access in pharmacies
Welsh, J. W., Yarbrough, C. R., Sitar, S. I., Mataczynski, M. J., Peralta, A. M., Kan, M., Crawford, N. D., Conrad, T. A., Kee, C., & Young, H. N. (2022) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2022.12.015 · Cited by 14
Healthcare Utilization of Patients with Opioid Use Disorder in US Hospitals from 2016 to 2019: Focusing on Racial and Regional Variances
Kim, S. J., Medina, M., & Chang, J. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01192-0 · Cited by 14
Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization
Skains, R. M., Reynolds, L. M., Carlisle, N. A., Heath, S. L., Covington, W., Hornbuckle, K. J., & Walter, L. A. (2023) · Western Journal of Emergency Medicine · doi:10.5811/westjem.60511 · Cited by 13
Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals
Franz, B. A., Dhanani, L. Y., Hall, O. T., Brook, D., Fenstemaker, C., Simon, J. E., & Miller, W. C. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00436-y · Cited by 13
The development of a recovery coaching training curriculum to facilitate linkage to and increase retention on medications for opioid use disorder
Moffitt, T., Fallin‐Bennett, A., Fanucchi, L. C., WALSH, S. L., Cook, C., Oller, D. A., Ross, A., Gallivan, M., Lauckner, J., Byard, J., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1334850 · Cited by 13
“They make it too hard and too many hoops to jump”: system and organizational barriers to drug treatment during epidemic rates of opioid overdose
Dickson‐Gómez, J., Krechel, S., Ohlrich, J., Montaque, H. D. G., Weeks, M. R., Li, J., Havens, J. R., & Spector, A. L. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-00964-5 · Cited by 13
Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial
Garland, E. L., Recasens, M., Taple, B. J., Donaldson, G. W., & Weisberg, R. B. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2392870 · Cited by 14
Randomized trial of methadone treatment of arrestees: 24-month post-release outcomes
Schwartz, R. P., Kelly, S. M., Mitchell, S. G., O’Grady, K. E., Duren, T., Sharma, A., Gryczynski, J., & Jaffe, J. H. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108392 · Cited by 13
Engagement in drug treatment following nonfatal overdose among people who inject drugs in Appalachia
Allen, S. T., Wedlock, P. T., White, R. H., Schneider, K. E., O’Rourke, A., Ahmad, N. J., Weir, B. W., Kilkenny, M. E., & Sherman, S. G. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103176 · Cited by 13
Criminal Problem-Solving and Civil Dependency Court Policies regarding Medications for Opioid use Disorder
Andraka‐Christou, B., Clark, M., Atkins, D. N., & del Pozo, B. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1944958 · Cited by 13
Factors Associated With Initial Treatment Choice, Engagement, and Discontinuation for Patients With Opioid Use Disorder
Mutter, R. L., Spencer, D. L., & McPheeters, J. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202100239 · Cited by 13
Self-citation
Treating Opioid Use Disorder in General Medical Settings
(2021) · Springer eBooks · doi:10.1007/978-3-030-80818-1 · Cited by 13
Attitudes on Methadone Utilization in the Emergency Department: A Physician Cross-sectional Study
Heil, J., Ganetsky, V. S., Salzman, M., Hunter, K. M., Baston, K., Carroll, G. G., Ketcham, E. M., & Haroz, R. (2022) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2022.2.54681 · Cited by 12
Methadone Dose, Cannabis Use, and Treatment Retention: Findings From a Community-based Sample of People Who Use Unregulated Drugs
Lake, S., Buxton, J. A., Walsh, Z., Cooper, Z. D., Socias, M. E., Fairbairn, N. S., Hayashi, K., & Milloy, M. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001032 · Cited by 13
Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease
Green, E. W., Byers, I. S., & Deutsch‐Link, S. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.09.017 · Cited by 14
Buprenorphine Treatment Intake and Critical Encounters following a Nonfatal Opioid Overdose
Victor, G. A., Bailey, K., & Ray, B. R. (2021) · Substance Use & Misuse · doi:10.1080/10826084.2021.1901933 · Cited by 13
Global burden, socioeconomic disparities, and spatiotemporal dynamics of opioid use disorder mortality and disability: a comprehensive analysis from the global burden of disease study 2017-2021
Zhang, J., Liu, R., Wang, X., Zhang, L., Pei, W., Hou, J., & Li, S. (2025) · BMC Public Health · doi:10.1186/s12889-025-24541-y · Cited by 13
Prepregnancy Care and Counseling
Cooper, K. M., Szymanski, L. M., David, P. S., Allen, S. V., & Breitkopf, D. M. (2026) · JAMA · doi:10.1001/jama.2026.2888 · Cited by 12
Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study
David, A. R., Sian, C. R., Gebel, C., Linas, B. P., Samet, J. H., Martinez, L. S. S., Muroff, J. R., Bernstein, J., & Assoumou, S. A. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108870 · Cited by 12
Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder
Foot, C. A., Korthuis, P. T., Tsui, J. I., Luo, S. X., Chan, B. L., & Cook, R. (2023) · Addiction · doi:10.1111/add.16334 · Cited by 12
Analysis of rising cases of adolescent opioid use presentations to the emergency department and their management
Sidlak, A. M., Dibble, B., Dhaliwal, M., Bottone, P. D., Marino, R. T., Henry, L. L., & Howell, J. M. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111136 · Cited by 12
Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder
Wyse, J. J. B., Eckhardt, A. C., Waller, D. E., Gordon, A. J., Shull, S., Lovejoy, T. I., Mackey, K., & Morasco, B. J. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001292 · Cited by 12
Attitudes toward medications for opioid use disorder among peer recovery specialists
Pasman, E., Lee, G., Singer, S., Burson, N., Agius, E., & Resko, S. M. (2024) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2024.2332597 · Cited by 12
Most States Allow Medicaid Managed Care Plans Discretion To Restrict Substance Use Disorder Treatment Benefits: Study examines Medicaid managed care plans’ restrictions on substance use disorder treatment
Peterson, L. A., Andrews, C. M., Abraham, A. J., Westlake, M. A., & Grogan, C. M. (2024) · Health Affairs · doi:10.1377/hlthaff.2023.01023 · Cited by 12
Comparison of Healthcare Resource Utilization Between Patients Who Engaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use Disorder
Velez, F. F., Colman, S., Kauffman, L., Ruetsch, C. R., Anastassopoulos, K. P., & Maricich, Y. A. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s334274 · Cited by 12
Innovating for real-world care: A systematic review of interventions to improve post-detoxification outcomes for opioid use disorder
Ameral, V., Hocking, E. C., Leviyah, X., Newberger, N. G., Timko, C., & Livingston, N. A. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109379 · Cited by 12
Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
Marciuch, A., Brenna, I. H., Weimand, B. M., Solli, K. K., Tanum, L., Røstad, B. K., & Birkeland, B. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00317-2 · Cited by 12
Coverage of the Opioid Crisis in National Network Television News from 2000–2020: A Content Analysis
Jay, J., Chan, A. R., Gayed, G., & Patterson, J. A. (2022) · Substance Abuse · doi:10.1080/08897077.2022.2074594 · Cited by 12
Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study
Hartung, D. M., Markwardt, S., Johnston, K. A., Geddes, J., Baker, R., Leichtling, G. J., Hildebran, C., Chan, B. L., Cook, R., McCarty, D. W., et al. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00318-1 · Cited by 14
Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021
del Pozo, B., Atkins, D. N., Andraka‐Christou, B., Wightman, R., Clark, M. H., Huynh, P., & Ray, B. R. (2023) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2023.100131 · Cited by 12
Antecedents of fatal overdose in an adult cohort identified through administrative record linkage in Indiana, 2015–2022
Ray, B. R., Christian, K., Bailey, T., Alton, M., Proctor, A., Haggerty, J., Lowder, E. M., & Aalsma, M. C. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109891 · Cited by 15
Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims
Xu, K. Y., Gertner, A. K., Greenfield, S. F., Williams, A. R., & Grucza, R. A. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00450-0 · Cited by 12
Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis
Savinkina, A. A., Madushani, R. W. M. A., Yazdi, G. E., Wang, J., Barocas, J. A., Morgan, J. R., Assoumou, S. A., Walley, A. Y., Linas, B. P., & Murphy, S. M. (2022) · Addiction · doi:10.1111/add.15879 · Cited by 12
Buprenorphine Treatment Duration and Adherence Among Youth and Subsequent Health Outcomes
Hadland, S. E., Kimmel, S. D., Yan, S., Bettano, A. L., Lo‐Ciganic, W., Bagley, S. M., Calihan, J. B., Hsu, H., & Larochelle, M. R. (2025) · PEDIATRICS · doi:10.1542/peds.2025-071147 · Cited by 11
Self-citation
Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage
Calcaterra, S. L., Lockhart, S., Natvig, C. L., & Mikulich, S. K. (2023) · Journal of Hospital Medicine · doi:10.1002/jhm.13193 · Cited by 12
Substance Use Disorder Program Availability in Safety-Net and Non–Safety-Net Hospitals in the US
Chang, J. E., Franz, B. A., Pagán, J. A., Lindenfeld, Z., & Cronin, C. E. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.31243 · Cited by 11
Women and Treatment for Opioid Use Disorder: Contributors to Treatment Success From the Perspectives of Women in Recovery, Women With Past Attempts in Drug Treatment, and Health and Criminal Justice Professionals
Skogseth, E. M., Brant, K., Harrison, E., Apsley, H. B., Crowley, D. M., Schwartz, R. P., & Jones, A. A. (2024) · Substance Use Research and Treatment · doi:10.1177/11782218231222339 · Cited by 12
Impact of Potential Case Misclassification by Administrative Diagnostic Codes on Outcome Assessment of Observational Study for People Who Inject Drugs
Goodman‐Meza, D., Goto, M., Salimian, A., SHOPTAW, S. J., Bui, A. A. T., Gordon, A. J., & Goetz, M. B. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae030 · Cited by 11
Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services
Bartholomew, T. S., Plesons, M., Serota, D. P., Alonso, E., Metsch, L. R., Feaster, D. J., Ucha, J., Suarez, E., Forrest, D. W., Chueng, T. A., et al. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00447-9 · Cited by 11
Insurance Instability for Patients With Opioid Use Disorder in the Year After Diagnosis
Christine, P. J., Goldman, A. L., Morgan, J. R., Yan, S., Chatterjee, A., Bettano, A. L., Binswanger, I. A., & Larochelle, M. R. (2024) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.2014 · Cited by 11
Self-citation
Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals
Shearer, R. D., Hagedorn, H., Englander, H. L., Siegler, T., Kibben, R., Fawole, A., Patten, A., Fitzpatrick, A., Laes, J. R., Fernando, J., et al. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209520 · Cited by 11
A Scoping Review of the Utilization of Opioid Use Treatment, Harm Reduction, and Culturally Tailored Interventions Among Racial/Ethnic Minorities in the United States
Ezell, J. M., Simek, E., Shetty, N., Pho, M. T., Bluthenthal, R. N., Goddard‐Eckrich, D., & Choi, S. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01373-2 · Cited by 13
Effect of acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, and estrus phase on cue- and drug-induced fentanyl seeking in female rats
Urbanik, L. A., Booth, J. L., Acharya, N., Evans, B., & Grigson, P. S. (2024) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000805 · Cited by 12
The opioid epidemic in rural communities: Can telehealth increase access to medications for opioid use disorder and offset barriers to care?
Meyers, K., Herman, S., Schuler, H., Mun, C. C., Bresani, E., & Payne, R. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112628 · Cited by 11
A pilot implementation study to scale-up methadone in incarcerated persons with opioid use disorder and retain them on treatment after release in Moldova
Dorgay, C. E., Bromberg, D. J., Doltu, S., Litz, T., de Leon, S. J. G., Polonsky, M., Dvoryak, S., & Altice, F. L. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103683 · Cited by 11
The False Dichotomy of Pain and Opioid Use Disorder
Jones, K. F., & Mason, D. J. (2022) · JAMA Health Forum · doi:10.1001/jamahealthforum.2022.1406 · Cited by 11
Racial/ethnic residential segregation and the availability of opioid and substance use treatment facilities in US counties, 2009–2019
DiNardi, M., Swann, W. L., & Kim, S. Y. (2022) · SSM - Population Health · doi:10.1016/j.ssmph.2022.101289 · Cited by 11
Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study
Livingston, N. A., Sarpong, A., Sistad, R. E., Roth, C. E., Banducci, A. N., Simpson, T. L., Hyde, J. K., Davenport, M. J., & Weisberg, R. B. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209188 · Cited by 11
Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults
Elkington, K. S., Nunes, E. V., Schachar, A., Ryan, M. E., García, A., DeVelde, K. V., Reilly, D. M., O’Grady, M. A., Williams, A. R., Tross, S., et al. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108277 · Cited by 13
Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration
Crystal, S., Nowels, M., Olfson, M., Samples, H., Williams, A. R., & Treitler, P. C. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108546 · Cited by 11
Opioid Use Disorder Among Clients of Community Mental Health Clinics: Prevalence, Characteristics, and Treatment Willingness
Ober, A. J., Hunter, S. B., McCullough, C., Leamon, I. M., McCreary, M. P., Beas, I., Montero, A., Tarn, D. M., Bromley, E., Hurley, B., et al. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000818 · Cited by 11
Designing and validating a Markov model for hospital-based addiction consult service impact on 12-month drug and non-drug related mortality
King, C. A., Englander, H. L., Korthuis, P. T., Barocas, J. A., McConnell, K. J., Morris, C. D., & Cook, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256793 · Cited by 11
Case report: acute care management of severe opioid withdrawal with IV fentanyl
Azar, P., Westenberg, J. N., Ignaszewski, M. J., Wong, J. S. H., Isac, G., Mathew, N., & Krausz, M. R. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00305-6 · Cited by 11
Expanding the Team: Optimizing the Multidisciplinary Management of Drug Use-Associated Infective Endocarditis
O’Donnell, M., Englander, H. L., Strnad, L. C., Bhamidipati, C. M., Shalen, E. F., & Riquelme, P. A. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07313-3 · Cited by 11
A discussion of critical errors in a longitudinal study on the deterrent effect of drug‐induced homicide laws on opioid‐related mortality across 92 counties and the District of Columbia in the United States
Carroll, J. J., Bevis, L. E. M., El‐Sabawi, T., Figgatt, M. C., Dasgupta, N., Beletsky, L. A., Leiberman, A. J., Dennis, A., & Davis, C. S. (2023) · World Medical & Health Policy · doi:10.1002/wmh3.570 · Cited by 9
Reducing overdose deaths among persons with opioid use disorder in connecticut
Scheidell, J. D., Townsend, T., Zhou, Q., Manandhar-Sasaki, P., Rodriguez-Santana, R., Jenkins, M. G., Buchelli, M., Charles, D. L., Frechette, J. M., Su, J. I.-S., et al. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-01026-6 · Cited by 12
Effect of a peer‐led emergency department behavioral intervention on non‐fatal opioid overdose: 18‐month outcome in the Navigator randomized controlled trial
Chambers, L. C., Li, Y., Hallowell, B. D., Langdon, K. J., Samuels, E. A., Mahoney, L., Beaudoin, F. L., & Marshall, B. D. L. (2024) · Addiction · doi:10.1111/add.16581 · Cited by 10
Harm Reduction in the Field: First Responders’ Perceptions of Opioid Overdose Interventions
Fockele, C. E., Frohe, T. M., McBride, O., Perlmutter, D. L., Goh, B. Y., Williams, G., Wettemann, C., Holland, N., Finegood, B., Oliphant-Wells, T., et al. (2024) · Western Journal of Emergency Medicine · doi:10.5811/westjem.18033 · Cited by 10
Medicare Payment for Opioid Treatment Programs
Nakamoto, C. H., Huskamp, H. A., Donohue, J. M., Barnett, M. L., Gordon, A. J., & Mehrotra, A. (2024) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.1907 · Cited by 10
Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis
Chan, B. L., Cook, R., Levander, X. A., Wiest, K. L., Hoffman, K. A., Pertl, K., Petluri, R., McCarty, D. W., Korthuis, P. T., & Martin, S. A. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209511 · Cited by 11

Authors: Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M.
Affiliations: Harvard University (US)
Boston University (US)
Integrated Programs, OptumLabs Inc, Cambridge, Massachusetts
Optum (United States) (US)
Department of Research, OptumLabs, Cambridge, Massachusetts
Department of Research, Optum Behavioral Health, Cambridge, Massachusetts
UnitedHealth Group (United States) (US)
Corresponding author: Wakeman, Sarah E.
ORCID: Wakeman, Sarah E.
Larochelle, Marc R.
Ameli, Omid
Chaisson, Christine E.
Crown, William H.
Azocar, Francisca
Sanghavi, Darshak M.
Venue: JAMA Network Open
Publisher: American Medical Association (AMA)
Published: 2020-02-05
Volume: 3
Issue: 2
Pages: e1920622
ISSN: 2574-3805 (ISSN-L)
DOI: 10.1001/jamanetworkopen.2019.20622
PMC: PMC11143463
OpenAlex: W3005454586
Cited by: 995
References: 39
Citations by year: 2026: 137 · 2025: 170 · 2024: 192 · 2023: 161 · 2022: 158 · 2021: 128 · 2020: 49
FWCI: 92.82
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
Locations: JAMA Network Open (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Massachusetts General Hospital
School of Medicine, Boston University (1UL1TR001430)
Laura and John Arnold Foundation
Office of National Drug Control Policy (G1799ONDCP06B)
Hamilton Health Sciences Foundation
National Institutes of Health (UL1TR001430)
Centers for Disease Control and Prevention (U01CE002780)
U.S. Food and Drug Administration (HHSF223200910006I)
Substance Abuse and Mental Health Services Administration (1H79TI081442-01)
National Institute on Drug Abuse (K23DA042168, R01DA044526, UG1DA015831, G1799ONDCP06B)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords: opioid use disorder, medication-assisted treatment, buprenorphine, methadone, naltrexone, inpatient detoxification, residential treatment, opioid overdose, acute care utilization, treatment pathways, comparative effectiveness, real-world evidence, injection-related infections
MeSH terms: Adolescent, Adult, Analgesics, Opioid, Behavior Therapy, Buprenorphine, Female, Humans, Male, Methadone, Middle Aged, Opioid-Related Disorders, Retrospective Studies, United States, Proportional Hazards Models, Substance Abuse Treatment Centers, Treatment Outcome, Critical Pathways, Young Adult, Comparative Effectiveness Research, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative effectiveness of different treatment pathways for opioid use disorder.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks